AstraZeneca shares fell sharply in London trading as market sentiment turned sour over the prospect of a merger with US rival Bristol-Myers Squibb.
The decline reflects growing investor skepticism regarding the strategic fit and regulatory hurdles associated with combining two of the world’s largest pharmaceutical companies.
AstraZeneca has shed more than £20 billion in market capitalization in recent sessions as the merger narrative has developed.
The sell-off accelerated after reports emerged that the two firms are in advanced discussions regarding a potential combination.
Despite the scale of the proposed deal, traders appear to be pricing in significant execution risk.
The market reaction suggests that investors view the merger as a potential value trap rather than a clear path to growth, particularly given the complex regulatory landscape in both the US and Europe.
AstraZeneca has shed more than £20 billion in market capitalization in recent sessions as the merger narrative has developed.